Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-350.57m
- Incorporated2020
- Employees5.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | 7.10m | -39.43m | 20.24m | 22.00 | -- | 0.3919 | -- | 2.85 | -0.9598 | -0.9598 | 0.1728 | 1.25 | 0.0798 | -- | -- | 244,862.10 | -44.28 | -41.24 | -55.51 | -46.49 | -- | -- | -555.23 | -1,774.39 | -- | -121.12 | 0.0399 | -- | -- | -- | -3.77 | -- | -- | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 20.53m | 22.00 | -- | 1.88 | -- | 2.05 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -27.73m | 20.68m | 8.00 | -- | 1.60 | -- | -- | -4.77 | -4.77 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -114.20 | -95.57 | -159.68 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 20.96m | 12.00 | -- | 1.65 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 21.14m | 46.00 | -- | 1.30 | -- | 15.63 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| GlycoMimetics Inc | 10.00k | -39.74m | 21.28m | 35.00 | -- | 1.87 | -- | 2,127.97 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 21.81m | 100.00 | -- | 0.3029 | -- | 2.23 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 22.27m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 22.58m | 4.00 | -- | 8.75 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.65m | 17.00 | -- | 2.08 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 22.65m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 23.91m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 24.05m | 4.00 | -- | 5.25 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Exicure Inc | 500.00k | -4.01m | 24.31m | 6.00 | -- | 15.73 | -- | 48.62 | -2.26 | -2.26 | 0.282 | 0.7112 | 0.0424 | -- | 0.4852 | 83,333.34 | -33.98 | -41.52 | -45.26 | -55.78 | -- | -- | -801.40 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Aeon Biopharma Inc's reporting currency: US Dollar USD
14.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 30 Sep 2024 | 3.60m | 9.11% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 744.10k | 1.88% |
| Formidable Asset Management LLCas of 30 Sep 2024 | 389.78k | 0.99% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 260.41k | 0.66% |
| Ikarian Capital LLCas of 30 Sep 2024 | 257.98k | 0.65% |
| Geode Capital Management LLCas of 30 Sep 2024 | 243.17k | 0.62% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 166.60k | 0.42% |
| Two Sigma Investments LPas of 30 Sep 2024 | 65.21k | 0.17% |
| The Caprock Group LLCas of 30 Sep 2024 | 62.69k | 0.16% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 60.95k | 0.15% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
